This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Labs Defends Pricing Policy

"Although the NIH could set a precedent, the circumstances are pretty unique to Abbott," said Hamill, who focuses on medical equipment companies (including some like Abbott and Baxter International (BAX) that also produce drugs) rather than the pure-play pharmaceutical companies.

Even the worst-case result would seem to have little impact on Abbott. Norvir had less than $100 million in sales last year. The drug's revenue is low enough so that Norvir doesn't show up in the quarterly list of top-selling drugs that Abbott publishes when it releases its earnings reports. For example, in 2003 Abbott identified its top 11 drugs in the United States and/or foreign markets, with the 11th ranked drug having $132 million in sales.

Abbott disputed attempts to apply a provision of a 1980 federal law, known as the Bayh-Dole Act, to Norvir, adding that the law "was never intended to be a tool for controlling pharmaceutical prices." The law was aimed at encouraging cooperation between private and public entities, the company said. The only time the government could revoke the license of a product under patent was if a company that benefited from public collaboration "has not successfully commercialized the invention as a product," Abbott said.

Asserting that its scientists "discovered, developed and funded Norvir," Abbott said that it had received only "a small discovery grant" from NIH totaling $3.47 million, primarily for preclinical work. Abbott spent more than $300 million to develop the drug.

Abbott said it raised its price of Norvir because the company discovered that the drug has an added attraction -- it can boost the activity of other HIV/AIDS drugs. That's why the company raised the price of Norvir to $8.57 a day from $1.71 a day in December. The price increase triggered the petition to the NIH, and critics have complained that Abbott was trying to squeeze more money out of an older drug.

Abbott also pointed out Monday that the new price for Norvir is still less than half of the company's newer HIV/AIDS drug Kaletra, and even cheaper than other drugs in Norvir's class made by Pfizer (PFE), Bristol-Myers Squibb (BMY) and GlaxoSmithKline (GSK). Abbott added that it has taken steps "to enhance access and affordability" for patients who lack health insurance and patients whose insurance doesn't cover the full cost of treatment.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $38.49 1.00%
AAPL $93.21 -0.44%
FB $117.80 -0.22%
GOOG $701.26 0.80%
TSLA $211.34 -5.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs